Loading…
Reliance Pharma Fund
Disclosed for 84 months, Sep 2012 to Aug 2019. This scheme is no longer reporting.Published as: RELIANCE PHARMA FUND (An Open Ended Equity Scheme Investing In Pharma Sector)
Portfolio value
₹853 Cr
up ₹74.2 Cr vs May 2014
- Stocks held
- 16
- unchanged
- Top 10 weight
- 85.5%
- of the portfolio in its ten largest
Reliance Pharma Fund is an active equity fund in the Sectoral / Thematic category from Nippon India Mutual Fund. In June 2014 it disclosed 16 stocks worth ₹853 Cr, up ₹74.2 Cr from May 2014. Its largest positions were Divi's Laboratories Limited (11.0%), Abbott India Limited (10.8%), Sanofi India Limited (10.6%); the ten largest together made up 85.5% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 95.1% of its equity. Cash and debt stood at 0.7%. Compared with May 2014 the fund entered 0 new stocks and exited 0.
Against 227 other Sectoral / Thematic funds
Concentration
100%
Top-10 weight is higher than 100% of peers
Breadth
2%
Holds more stocks than 2% of peers
Cash
9%
Holds more cash than 9% of peers
Holdings in June 2014
Download CSVEvery line the fund disclosed, with the change against May 2014. Click a column to sort; click a company to see every fund that owns it.
| Divi's Laboratories Limited | 10.95% | up 0.06 pts | ₹93.4 Cr | up ₹8.6 Cr | Added |
| Abbott India Limited | 10.82% | up 1.35 pts | ₹92.3 Cr | up ₹18.5 Cr | Added |
| Sanofi India Limited | 10.63% | down 2.13 pts | ₹90.6 Cr | down ₹8.7 Cr | Trimmed |
| Zydus Lifesciences Limited | 10.43% | up 0.46 pts | ₹88.9 Cr | up ₹11.4 Cr | Added |
| Lupin Limited | 9.84% | down 0.03 pts | ₹83.8 Cr | up ₹7.1 Cr | Added |
| Dr. Reddy's Laboratories Limited | 8.47% | down 1.02 pts | ₹72.2 Cr | down ₹1.7 Cr | Trimmed |
| Sun Pharmaceutical Industries Limited | 8.07% | up 0.81 pts | ₹68.8 Cr | up ₹12.3 Cr | Added |
| Cipla Limited | 7.50% | up 0.29 pts | ₹64 Cr | up ₹7.8 Cr | Added |
| Biocon Limited | 4.98% | up 0.49 pts | ₹42.5 Cr | up ₹7.5 Cr | Added |
| Indoco Remedies Limited | 3.80% | down 0.32 pts | ₹32.4 Cr | up ₹35 L | Added |
| Procter & Gamble Health Limited | 3.33% | up 0.18 pts | ₹28.4 Cr | up ₹3.9 Cr | Added |
| IPCA Laboratories Limited | 3.09% | down 1.18 pts | ₹26.3 Cr | down ₹6.9 Cr | Trimmed |
| FDC Limited | 2.47% | up 0.05 pts | ₹21 Cr | up ₹2.3 Cr | Added |
| Sun Pharma Advanced Research Company Limited | 2.32% | down 0.11 pts | ₹19.8 Cr | up ₹86 L | Added |
| Alembic Pharmaceuticals Limited | 1.53% | up 0.73 pts | ₹13 Cr | up ₹6.9 Cr | Added |
| Fulford India Ltd | 1.07% | up 0.04 pts | ₹9.1 Cr | up ₹1.1 Cr | Added |
| Cash, TREPS & receivables | 0.70% | up 0.32 pts | ₹5.9 Cr | up ₹3 Cr | Added |
What changed, May 2014 to Jun 2014
New New positions (0)
None.
Exited Exited (0)
None.
Added Biggest additions
- Abbott India Limitedup ₹18.5 Cr (+1.35% pts)
- Sun Pharmaceutical Industries Limitedup ₹12.3 Cr (+0.81% pts)
- Zydus Lifesciences Limitedup ₹11.4 Cr (+0.46% pts)
- Divi's Laboratories Limitedup ₹8.6 Cr (+0.06% pts)
- Cipla Limitedup ₹7.8 Cr (+0.29% pts)
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since May 2014, the weight rose most in Pharmaceuticals & Biotechnology (+0.3 pts), and fell most in Pharmaceuticals (−0.3 pts).
- Pharmaceuticals & Biotechnology94.8% → 95.1%+0.3 pts
- Pharmaceuticals4.1% → 3.8%−0.3 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Jun 2013 | Dec 2013 | Mar 2014 | May 2014 | Jun 2014 |
|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 79.2% | 84.6% | 92.8% | 94.8% | 95.1% |
| Pharmaceuticals | 14.3% | 9.1% | 4.0% | 4.1% | 3.8% |
| Miscellaneous | 1.1% | 0.9% | 0.5% | 1.0% | 1.1% |
Allocation in Jun 2014change vs May 2014
- Pharmaceuticals & Biotechnology (14)95.1%▲ 0.3 pts
- Pharmaceuticals (1)3.8%▼ 0.3 pts
- Miscellaneous (1)1.1%
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal.
Cash & debt, Jun 2014
0.7%
▲ 0.3 pts vs May 2014
- Cash alone
- 0.7%
- cash and net receivables
- A year earlier
- 0.7%
- Jun 2013
- Last 12 months
- 0.3% – 2.9%
- lowest to highest · record 2.9% in Feb 2014
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.